| 1. |
- Carr, Victoria R., et al.
(author)
-
Abundance and diversity of resistomes differ between healthy human oral cavities and gut
- 2020
-
In: Nature Communications. - : NATURE PUBLISHING GROUP. - 2041-1723. ; 11:1
-
Journal article (peer-reviewed)abstract
- The global threat of antimicrobial resistance has driven the use of high-throughput sequencing techniques to monitor the profile of resistance genes, known as the resistome, in microbial populations. The human oral cavity contains a poorly explored reservoir of these genes. Here we analyse and compare the resistome profiles of 788 oral cavities worldwide with paired stool metagenomes. We find country and body site-specific differences in the prevalence of antimicrobial resistance genes, classes and mechanisms in oral and stool samples. Within individuals, the highest abundances of antimicrobial resistance genes are found in the oral cavity, but the oral cavity contains a lower diversity of resistance genes compared to the gut. Additionally, co-occurrence analysis shows contrasting ARG-species associations between saliva and stool samples. Maintenance and persistence of antimicrobial resistance is likely to vary across different body sites. Thus, we highlight the importance of characterising the resistome across body sites to uncover the antimicrobial resistance potential in the human body. Antimicrobial resistance (AMR) represents a global health threat. Here, the authors analyse the oral and gut resistomes from metagenomes of diverse populations and find that the oral resistome harbours higher abundance but lower diversity of antimicrobial resistance genes than the gut resistome.
|
|
| 2. |
- Proffitt, Ceri, et al.
(author)
-
Disease, Drugs and Dysbiosis : Understanding Microbial Signatures in Metabolic Disease and Medical Interventions
- 2020
-
In: Microorganisms. - : MDPI. - 2076-2607. ; 8:9
-
Research review (peer-reviewed)abstract
- Since the discovery of the potential role for the gut microbiota in health and disease, many studies have gone on to report its impact in various pathologies. These studies have fuelled interest in the microbiome as a potential new target for treating disease Here, we reviewed the key metabolic diseases, obesity, type 2 diabetes and atherosclerosis and the role of the microbiome in their pathogenesis. In particular, we will discuss disease associated microbial dysbiosis; the shift in the microbiome caused by medical interventions and the altered metabolite levels between diseases and interventions. The microbial dysbiosis seen was compared between diseases including Crohn's disease and ulcerative colitis, non-alcoholic fatty liver disease, liver cirrhosis and neurodegenerative diseases, Alzheimer's and Parkinson's. This review highlights the commonalities and differences in dysbiosis of the gut between diseases, along with metabolite levels in metabolic disease vs. the levels reported after an intervention. We identify the need for further analysis using systems biology approaches and discuss the potential need for treatments to consider their impact on the microbiome.
|
|
